Introduction
Among n-3 polyunsaturated fatty acid (n-3 PUFA), docosahexaenoic acid (DHA, 22:6n-3) has generated increasing interest due to its ability to decrease resistance of experimental mammary tumors to anthracyclines or radiotherapy without additional side effects (reviewed in refs 1-3). In two Phase II studies, dietary supplementation with n-3 PUFA has led to an increased survival and chemotherapy efficacy without affecting the toxicity profile of the conventional chemotherapy (4, 5) . Different molecular mechanisms such as the amplification of the oxidative stress generated by anthracyclines or radiotherapy have been proposed to account for these effects (6, 7) .
Some studies have reported a reduced quantity of vessels in n-3 PUFA-enriched tumors (8, 9) but there is no data reported in the literature on a potential effect of n-3 PUFA on the vessel quality. Up to now, the intriguing paradox of n-3 PUFA diet, inducing both a decreased vascularization of tumor and an enhancement of tumor sensitivity to anticancer drugs, has not been addressed experimentally. However, it has already been observed that the efficacy of chemotherapy or radiations were improved when a conventional antiangiogenic agent was used concomitantly (10) (11) (12) . Since the vascular quality in tumor is generally recognized to be poor, one would have anticipated that a further decreased vascularization would have led to a poor distribution of anticancer drug in tumors and to an increase in hypoxic areas known to be chemoresistant.
Recently, Jain et al. (13) (14) (15) developed and tested the idea that tumor vasculature was normalized during angiogenic therapy. Several experimental evidences indicated that antiangiogenic treatments, especially those directed against the vascular endothelial growth factor (VEGF) pathway, 'normalized' the abnormal structure and functions of tumor vasculature to make it more efficient for oxygen and drug delivery. This normalization was associated with a decrease in interstitial fluid pressure (IFP). In non-treated tumors, the induction of hyperpermeable vessels by VEGF and nitric oxide (NO) and a heterogenous blood flow led to elevation of IFP and hypoxia, two hallmarks of chemoresistance. The endothelial nitric oxide synthase (eNOS) is the NOS isoform responsible for hyperpermeability and tumor angiogenesis (16) . High IFP is an obstacle to anticancer drug diffusion and a decrease of IFP led to a deeper penetration of molecules (15, (17) (18) (19) . In agreement with the notion that IFP functions as a barrier to drug delivery, high tumor IFP has in some instance been shown to be associated with a poor response to treatment in patients. For example, in a study of patients with melanoma, all responders displayed a lower tumor IFP compared to non-responders (20) . IFP has also been used as a prognostic factor and was found to be a best predictor (compared with oxygen pressure) of survival in patients with cancer of the uterine cervix (21) .
The effects of n-3 PUFA during taxane therapy such as docetaxel, frequently used in cancer treatment, have not been explored so far. Using induced autochthonous mammary tumors, a rat model expressing the constituents of tumor stroma including vessels, we investigated how n-3 PUFA can (i) restore a functional vascularization, (ii) potentiate the efficiency of docetaxel and (iii) modify the NO signaling pathway involved in angiogenesis and vessel permeability.
Materials and methods
Experimental design, carcinogenesis initiation and diets All animal studies and experimental procedures were approved by the Animal Care Committee of Région Centre and Centre de Recherches Biologiques. Female Sprague-Dawley rats aged 6 weeks (Harlan, Gannat, France) received a single subcutaneous dose (25 mg/kg) of N-methylnitrosourea (Sigma, Saint Quentin-Fallavier, France) to initiate mammary carcinogenesis (22, 23) . Rats (n 5 110) were then separated equally into a control group or an n-3 PUFA group. The control group was fed with a diet containing peanut (12%) and rape (3%) oils (%, g/100 g of diet). The n-3 PUFA group was fed with a diet containing peanut (8%), rape (2%) and fish (5%) oils (Phosphotech, Saint Herblain, France), which is composed of 50% DHA and 20% eicosapentaenoïc acid. When tumors reached 1.5-2 cm 2 ($8 weeks after carcinogenesis initiation), some rats (n 5 24) were euthanized after the measurement of oxygen partial pressure. Tumors were cryopreserved for fatty acids and molecular analysis. Remaining rats (n 5 66) were used to evaluate chemotherapy efficacy and vascular quantity or to measure IFP and Evans blue extravasation. At the end of chemotherapy protocol, tumors were also cryopreserved for fatty acids and molecular analysis (summary of experimental design in Figure 1 ). When mammary tumors reached 2 cm   2 , rats (n 5 21 per nutritional group) were submitted to docetaxel treatment (TaxotereÒ, Sanofi Aventis, France; 6 mg/kg/week intraperitoneal) for 6 weeks. Rats were examined weekly and tumor area was calculated using the two largest diameters (Ø1 and Ø2) according to the ellipse formula: tumor area 5 p (Ø1 Â Ø2)/4.
Docetaxel treatment

Functional vascular quantification
Tumor vascularization was investigated with both power Doppler ultrasound and contrast-enhanced ultrasound (CEUS) on rats (15 , n , 20) . Ultrasound examinations were performed at three time points: prior to the first injection (W 0 ), after 2 weeks (W þ2 ) and after 6 weeks of docetaxel injection (W þ6 ).
For power Doppler, the ultrasound machine (Esaote, Italy) was equipped with a 4-13 MHz linear probe (LA 523; Esaote). Gain and velocity scales remained stable over experiments. Tumor vascularization density was quantified under MATLABÒ software (MathWorks TM , Meudon, France) using the power Doppler index (PDI), which is a ratio between colored pixels and total pixels of the region of interest (ROI, defined as the tumor contours) expressed in % (24) . The mean of PDI was obtained from the five stored images of a tumor.
CEUS ultrasound data were acquired with a dedicated CnTI TM technology (Contrast Tuned Imaging; Esaote) using a Technos scanner equipped with a 5-10 MHz probe (LA 532; Esaote). Microbubbles of SonoVueÒ (Bracco Imaging SpA, Milano, Italy) were used as contrast agent (0.3 ml, 45 lg/ml, intravenous bolus injection) (25) . Due to the important echogenicity and specific properties of the ultrasound contrast agent, CEUS detects only functional vessels (from large to small vessels) in which the contrast agent is able to flow. CEUS signal on video clip of manually drawn region of interest was analyzed with Visilog.6Ò software (Noesis, Saint Aubin, France), enabling the determination of the time (s)-intensity (dB) curve. Area under the curve (AUC), amplitude of peak (representatives of vascular volume) and tumor blood flow were calculated.
Oxygen partial pressure and carbonic anhydrase IX analysis in tumors Tumor oxygen pressure (PO 2 ) was measured using a polarographic microprobe (LICOXÒ system). Docetaxel-treated (W þ6 ) and untreated rats (W 0 -10 tumors minimum per nutritional group) were evaluated. Data were captured by LICOX CMP software. The mean of oxygen pressure was obtained from measurements acquired in three different points of the tumor. To corroborate oxygen pressure measurements, we quantified carbonic anhydrase IX (CAIX) messenger RNA (mRNA) level, an hypoxia-inducible gene. Total RNAs from tumor samples were extracted with TRIzol reagent (Invitrogen, France) and reverse transcribed ('Ready-to-go'; GE Healthcare). Quantitative real-time polymerase chain reaction was carried out with MyiQ thermocycler (BioRad, France) using PlatinumÒ SYBRÒ Green qPCR SuperMix-UDG kit (Invitrogen). The primer sequences of rat CAIX were 5#-CTT GGA AGA AAT CGC AGA GG-3# (sense) and 5#-GCA ACA GTG CAG ATA CAT CCA-3# (antisense). HPRT and Rpl13 expression were used as reference (5#-CAG GCC AGA CTT TGT TGG AT-3# and 5#-TCC ACT TTC GCT GAT GAC AC-3', 5#-CTG TGG CAG GGT CTA AAATG-3# and 5#-TCG AAG ACATTC TGG TAG GG-3#, respectively). Polymerase chain reaction protocol was 10 min start at 95°C, followed by 40 cycles of 15 s at 95°C, 30 s at 57°C, and 1 min at 72°C. Using the comparative cycle threshold (CT) method (CT value), the amount of mRNAs was expressed as ÀDCT [CT CAIX-CT (mean HPRT-RPL13)].
Tumor IFP measurement and Evans blue extravasation When the surface area of mammary tumors (8 , n , 11 per nutritional group) reached at least 2 cm 2 , tumors were instrumented according to the technical method described by Schnell et al. (26) . The radio telemetry system used in this study was composed of four basic components: an implantable transmitter (model: TL11M2-C50-PXT; Data Science) that continuously transmitted information, a receiver located under the cage, a matrix interface for coordination of signals, and an ART TM computerized acquisition system (Data Science) for collection, analysis and storage of data. Under anesthesia (2.5% isoflurane in O 2 ) and in aseptic conditions, the sterile transmitter was placed in the peritoneal cavity of the animal and the sensing pressure catheter was implanted at 0.5 cm of depth into the body of the tumor and secured at the site of entry with tissue adhesive (HistoacrylÒ; B. Braun Medical, France). The animals were allowed to recover from the surgery for 24 h before starting data acquisition. IFP measures were stabilized for 6 days after instrumentation. Then, animals received a single dose of docetaxel (intraperitoneal, 6 mg/kg). Pressure data were recorded every 10 s at 500 Hz with the acquisition system, and for each rat, mean of IFP values were realized every 2 h for 1 week (W þ1 ). At W þ1 , the dye Evans blue (27) was used to monitor molecules extravasation in tumors of each dietary group (n 5 5 per group). Briefly, Evans blue solution (25 mg/kg in saline; Sigma) was injected in the tail vein of rat anesthetized with sodium pentobarbital (45 mg/kg, intraperitoneal; CEVA, France) and rats were euthanized 30 min later. Evans blue fluorescence (Ex 620 nm, Em 680 nm) was used to quantify dye extravasation and evaluated on 20 lm tumor sections mounted onto glass side using an epi-fluorescence microscope equipped with a Â10 objective field (Nikon 'Eclipse Ti-S' microscope, Nikon 'CFI Fig. 1 . Summary of experimental design. Rats received a single dose of N-methylnitrosourea to initiate mammary carcinogenesis. Rats (n 5 110) were separated equally into a control or an n-3 PUFA diet group. When tumors reached $2 cm 2 (W 0 ), rats were euthanized after oxygen measure or submitted to docetaxel treatment with one injection/week (arrow). Functional vascular and molecular parameters were determined at time points indicated in the layout before (W 0 ) and after 1 (W þ1 ), 2 (W þ2 ) or 6 weeks (W þ6 ) of docetaxel therapy.
n-3 PUFA potentiate docetaxel treatment by decreasing IFP 160 Â10' objectives, Nikon Digital Camera 'DXM1200F'). Three pictures per tumor were captured with NIS-Elements software (version 3.0). Evans blue intensity was quantified using Leica system software (Qwin, version 3.4.4).
Fatty acids analysis of tumor tissues
Two hundred milligrams of tumor tissue (n 5 8 per group) were frozen at À80°C in a methanol: chloroform solution (2:1). The fatty acid composition of phospholipids was determined by capillary gas chromatography (GC Trace; Thermo Scientific) as previously described (28) .
Endothelial cell culture, migration and permeability assays Human umbilical vein endothelial cell (HUVEC; Promocell, Germany) were cultured in endothelial cell growth medium (Endothelial Cell Growth Medium C22110; Promocell) and were used up to the fifth passage. HUVEC were seeded at the density of 1500 cells/cm 2 and enriched with 5 lM DHA (Sigma-Aldrich, France) or treated with vehicle (ethanol) for 5 days. For migration assay, 25 000 HUVEC in serum-free medium were seeded in the upper side of the Boyden chamber (polyethylene filter with 8 lm pore; Becton Dickinson). Serum gradient was obtained by filling the lower side of the Boyden chamber with complete medium MV (Promocell) with or without VEGF (10 ng/ml). Deta-NO (SigmaAldrich) was used at 10 lM. After 5 h, HUVEC on lower side were fixed, stained with hematoxylin and counted. Results are expressed as a percentage of migrating HUVEC compared with the control condition (vehicle-treated HUVEC). For permeability assay, 5000 HUVEC were seeded on fibronectin-coated Boyden chamber. HUVEC were treated with 1 lM DHA or with vehicle during 6-7 days until they reached confluence. After serum starvation (4 h), fluorescein isothiocyanate (FITC)-dextran (1 mg/ml, molecular weight 40 kDa; Sigma) was added in the upper compartment. After 1 h, VEGF (10 ng/ml) was, or not, added for an additional hour. FITC-dextran leakage through endothelial monolayer was evaluated after each incubation by measuring FITC-dextran quantity in lower chamber with spectrofluorometer (Ex 492/Em 520 nm; Hitachi). Results are expressed as ratio of quantity of FITC between both incubation periods (lg FITC 2 h /lg FITC 1 h ).
Westernblotting analysis of Ser1177 eNOS phosphorylation HUVEC were seeded at the density of 1500 cells/cm 2 and enriched with 5 lM DHA or treated with vehicle (ethanol) for 5 days. VEGF (10 ng/ml) was added 1 h before cells scrapping in lysis buffer (Tris 50 mM, pH 7.5, NaCl 150 mM, ethyleneglycol-bis(aminoethylether)-tetraacetic acid 1 mM, Nonidet P40 1%, antiphosphatases and antiproteases cocktail; Sigma-Aldrich). Proteins from tumors were extracted with the same lysis buffer. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred on a polyvinylidene difluoride membrane (Millipore, France). Membranes were incubated with goat antibody anti-Ser1177P-eNOS or anti-pan-eNOS (Tebu-Bio, France) (29) . Antibodies were revealed with chemiluminescence reagent (ECL reagent; Fisher Scientific, France). Densitometric analyses were performed using Quantity OneÒ software v4.6.3 (Bio-Rad).
Statistical analysis
Statistical analyses were carried out using an analysis of variance with repeated measurements followed by post hoc Fisher least significant difference test for monitoring of IFP and tumor size. Spearman test was used for correlation. Analysis of variance/Newman-Keuls and Mann-Whitney tests were used, respectively, for in vitro assays and molecular analysis (GraphPad Prism; GraphPad Software, La Jolla, CA); P , 0.05 was considered to be significant.
Results
n-3 PUFA diet enhanced DHA and eicosapentaenoic acid level in tumor tissues Fatty acids composition of tumor phospholipids (Table I) showed a 2.5-fold increase of total n-3 PUFA (P , 0.001) in the n-3 PUFA group compared with control group, with a 1.7-fold enrichment in DHA (22:6n-3, P , 0.001). Although eicosapentaenoic acid (20:5n-3) was undetectable in control rats, its level reached 1.1 ± 0.15% in the n-3 PUFA group (P , 0.001). The n-3 PUFA group showed a decrease by 25% of n-6 PUFA amount (P , 0.001), especially for arachidonic acid (20:4n-6), which was reduced by 1.5-fold. A weak increase in monounsaturated (13%, P , 0.05) was observed in the n-3 PUFA group. No modifications were detected in saturated fatty acids.
n-3 PUFA diet increased tumor response to docetaxel treatment and decreased tumor vascularization The effect of the n-3 PUFA diet, compared with the control diet, on the tumor size during docetaxel therapy is presented in Figure 2 . With the control diet (left), tumor growth under docetaxel was stopped and stabilized at 2.1 cm 2 . With the n-3 PUFA diet (right), the chemotherapy led to a tumor size regression significantly different from 2 to 6 weeks compared with control group. The tumor regression reached 50% at the end of chemotherapy (P , 0.01) without additional adverse effects (no significant difference in blood formula and animal weight was observed between the two nutritional groups). In the absence of docetaxel treatment, the n-3 PUFA diet did not modify tumor growth (Supplementary Figure 1 , available at Carcinogenesis Online).
Ultrasound parameters have been used to quantify the tumor vascularization. Power Doppler ultrasound allowed quantifying the larger vessels, whereas CEUS allowed quantifying the total tumor vascularization including microvessels (Table II) . At W 0 , before the first injection of docetaxel, peak intensity, AUC and blood flow (CEUS parameters) were, respectively, 26% (P , 0.05), 43% (P , 0.01) and 39% (P , 0.05) lower in the n-3 PUFA group than in the control group. PDI was slightly, but not significantly, lower at W 0 in the n-3 PUFA group compared with control. Docetaxel appeared to have a sequential effect on the tumor vascularization according to the time of treatment. Docetaxel at W þ2 led to an increase in CEUS parameters in the control diet group ($40% for peak intensity and AUC, P , 0.05 and 65% for blood flow, P , 0.001). These vascular changes induced by docetaxel at W þ2 were not detected in the n-3 PUFA group. At W þ6 , docetaxel displayed an antiangiogenic effect in both nutritional groups, with a more marked effect in the n-3 PUFA group. In control diet (W þ6 ), docetaxel led to a decrease of 37% for peak intensity (P , 0.05) and 52% for AUC (P , 0.001). In the n-3 PUFA group (W þ6 ), docetaxel led to a decrease of 50% in sonographic parameters (peak intensity, AUC) including PDI (P , 0.01 for all parameters). Whereas no significant difference in blood flow was observed in control diet at W þ6 (compared with W 0 ), a decrease of 70% in blood flow was observed in the n-3 PUFA group (P , 0.05).
n-3 PUFA diet reduced tumor IFP and increased Evans blue extravasation Figure 3A shows the variation of tumor IFP, from 1 day before to 7 days (W þ1 ) after a single docetaxel injection. Before docetaxel treatment, the IFP values were not statistically different between both nutritional groups and at docetaxel injection, the mean values were 15.2 ± 1.3 mmHg for control and 15.0 ± 1.9 mmHg for n-3 PUFA group. After docetaxel injection, in control group, IFP slightly decreased to 13.5 ± 1.1 mmHg (À11%) 24 h post-injection and to 12.9 ± 1.2 (À15%) at 48 h (compared with W 0 ). In n-3 PUFA group, IFP decreased rapidly and markedly 2 h (À14%) or 24 h (À26%) after docetaxel injection. IFP was $9.4 mmHg (À37%) in the PUFA group at the end of Day 2 (48 h) corresponding to a reduction of 27% compared with the control group (P , 0.01). At Day 7, the IFP values were stabilized without any further IFP difference between the both diet groups. To determine whether IFP may be an early biomarker for docetaxel efficacy, correlation between the percent of decrease in IFP at 48 h and the percent of tumor regression has been analyzed ( Figure 3A) . The two variables were moderately correlated (Spearman r 2 5 0.37) and close to statistical significance (P 5 0.057). The extravasation of Evans blue was assessed in each dietary group at W þ1 ( Figure 3B ). The fluorescence intensity of Evans blue was increased by 3-fold in tumors of the n-3 PUFA group compared with the control group (P , 0.05). These data were confirmed by the spectrofluorometric quantification of Evans blue extracted from tumors (Supplementary Figure 2 , available at Carcinogenesis Online).
The number of hypoxic tumors was evaluated with a polarographic probe. Before docetaxel treatment (W 0 ), the hypoxic tumor percentage (,10 mmHg) was the same in both nutritional groups (28 and 25% in control and n-3 PUFA groups, respectively). After docetaxel treatment (W þ6 ), none of the tumors of the two nutritional groups were hypoxic (data not shown). These results have been completed by an analysis of CAIX mRNA expression, an enzyme induced by hypoxia ( Figure 3C ). CAIX mRNA expression was significantly decreased by docetaxel treatment (P , 0.001) in the diet control group, indicating a decrease in hypoxia. At W þ6 , CAIX mRNA expression further decreased in the n-3 PUFA group (P , 0.05), suggesting an improvement of tumor oxygenation in tumors of the n-3 PUFA group under docetaxel treatment.
n-3 PUFA diet prevented endothelial NO synthase phosphorylation induced by docetaxel treatment Since angiogenesis and vasculature permeability are controlled in part by production and release of free radical gas NO, we hypothesized that n-3 PUFA-enriched diet might reduce eNOS activation. Western blot analyses of Ser1177P-eNOS and pan-eNOS were performed from tumor tissues in control and n-3 PUFA groups before (no docetaxel-W 0 ) and after docetaxel treatment (docetaxel-W þ6 ). Densitometry analyses (Ser1177P-eNOS/pan eNOS) showed no change in phosphorylation of Ser1177P-eNOS in the two nutritional groups before docetaxel treatment ( Figure 3D ). The phosphorylation of Ser1177P-eNOS was increased by $6-fold in the control nutritional group under docetaxel treatment (P , 0.01). Interestingly, this docetaxel-induced eNOS phosphorylation was repressed in the n-3 PUFA group since the median values were only increased by 2-fold in this group before (median 5 0.45) and after docetaxel treatment (median 5 1.02) (not statistically different).
DHA blocked the activation of endothelial cells by VEGF Since VEGF regulates tumor angiogenesis and vessel permeability, we wondered whether n-3 PUFA, such as DHA, could regulate VEGF signaling pathway in endothelial cells. We examined the effect of DHA on the permeability of HUVEC monolayer to FITC-labeled dextran ( Figure 4A ). Although VEGF increased the permeability of the monolayer by $3-fold in control cells (P , 0.001), this effect was not observed in DHA-supplemented HUVEC (P , 0.001). As expected (30) , VEGF increased HUVEC migration by 46% (P , 0.001) ( Figure 4B ). In DHA-supplemented HUVEC, the stimulation of migration by VEGF was markedly lower compared with the migration induced by VEGF in control cells (P , 0.001). This inhibition was abolished by the addition of exogenous NO (Deta-NO), suggesting an interaction of DHA with NO signaling pathway. Since the effects of VEGF are largely dependent on NO release, we have studied the , docetaxel was injected at 6 mg/kg/week (arrows, injections) and tumor size was measured once a week for 6 weeks. Points, mean of tumor size in each group (n 5 21), bars and standard error of the mean. Difference between control and n-3 PUFA diet: analysis of variance with repeated measurements followed by Fisher least significant difference test, Ã P , 0.05, ÃÃ P , 0.01.
n-3 PUFA potentiate docetaxel treatment by decreasing IFP phosphorylation level on ser1177-eNOS known to induce its activity. As anticipated, VEGF induced the phosphorylation of eNOS by 1.6-fold (P , 0.05) ( Figure 4C ). In DHA-supplemented cells, this phosphorylation of eNOS by VEGF was prevented (P , 0.05).
Discussion
Many solid tumors treated with chemotherapy present a high IFP that is associated to chemoresistance. Our study reports for the first time that PUFA, used as an adjuvant to standard chemotherapy, markedly improved the efficacy of taxanes. This chemosensitization of mammary tumors to taxanes was associated to the decrease of IFP, which is a major obstacle to effective delivery of anticancer agent within the tumor. These vascular effects of n-3 PUFA were further confirmed by a decreased activation of the eNOS in mammary tumors and in endothelial cells. It has been previously reported by us and others that n-3 PUFA display an antiangiogenic effect in rats (8,9) or in cell culture (31,32) . The reduction in tumor vascularization was accompanied by an enhancement of tumor sensitivity to anthracyclines (9) . In the present study, we showed that the therapeutic efficacy of taxanes was also markedly improved by n-3 PUFA supplementation. An important finding was that the tumor IFP was rapidly and steadily reduced in n-3 PUFA group after a single taxane injection. Tumor IFP is traditionally measured using the wick-in needle technique that can only be performed on anaesthetized animals, hence with limited time point. In the present study, a miniaturized radio-telemetry system has been used for a continuous recording of IFP as described by Schnell et al. (26) . IFP values measured within untreated tumors during this study were within the same order as those measured by wick-in needle in a similar rat mammary tumor model (33) . We showed that the decrease in tumor IFP in the n-3 group under docetaxel treatment preceded the tumor response to the anticancer drug. This supports the idea that IFP plays a major role in anticancer agent delivery and, as previously reported, it may be an early biomarker for drug efficacy (34, 35) . The movement of molecules from blood vessels to the interstitial space is governed by pressure gradients. Indeed, elevated IFP in tumors is considered to be a major barrier to the delivery of Fig. 3 . n-3 PUFA diet reduces tumor IFP, increased Evans blue extravasation and prevented endothelial NO synthase activation in tumors. (A) IFP evolution before and after docetaxel injection (on the left). Rats equipped with a pressure-sensing catheter inserted in the tumor were treated once with docetaxel. The graph presents IFP measured for 1 day before injection to 7 days post-injection. Point represents mean values ± SEM (in mmHg, n 5 11 in control, n 5 8 in PUFA group). The control group was compared with the PUFA group using an analysis of variance with repeated measurements followed by a Fisher least significant difference test;
Ã P , 0.05, ÃÃ P , 0.01. Correlations between the response to chemotherapy (% tumor regression) and the decrease in IFP 48 h after docetaxel injection (%) (on the right). Points: individual data measured for 19 tumors (Spearman test, P 5 0.057). (B) Evans blue extravasation in docetaxel-treated tumors. Tumor sections were analyzed and extravasated Evans blue was quantified by fluorescence intensity. Lines within boxes, median values (n 5 5 per group; three pictures/tumor), Ã P , 0.05, Mann-Whitney test. (C) CAIX mRNA level in tumors of two nutritional groups before (W 0 ) and after docetaxel treatment (W þ6 ). Quantitative polymerase chain reaction results are expressed in ÀDCt, with lines as median values, 13 , n , 17 per group.
Ã P , 0.05, ÃÃÃ P , 0.001 analysis of variance followed by Newman-Keuls test. (D) Effect of docetaxel and n-3 PUFA on eNOS phosphorylation in tumors. Tumor extracts were analyzed by western blotting for Ser1177-PeNOS and pan eNOS expression in the two nutritional groups prior (W 0 ) or after docetaxel (W þ6 ) treatment. Results were quantified by densitometry and expressed by the ratio P-eNOS/pan eNOS (no docetaxel: between 6 , n , 8 per nutritional group; with docetaxel between 11 , n , 12 per nutritional group) with lines as median values, ÃÃ P , 0.01, analysis of variance followed by Newman-Keuls test.
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chemotherapeutics (36) . Several studies showed that the uptake of anticancer agents (5-fluorouracil, taxol, CPT11 and topotecan) in rodent tumors was increased when the IFP was pharmacologically lowered (18, 19, 37, 38) . For example, a 40% reduction in IFP 1 h after platelet-derived growth factor receptor antagonist administration was associated with an increase in taxol uptake by 4-fold at 24 h (19). In our study, the more marked decrease of IFP in n-3 PUFA tumors (À25% compared to control) was associated with an increase by 3-fold of Evans blue extravasation. These results are consistent with those of Tong et al. (39) who showed that a decrease in IFP by anti-VEGFR2 monoclonal antibody was associated with a significantly deeper penetration of molecules into the rodent tumors. Thus, an increase of docetaxel delivery in mammary tumors subsequent to a lower IFP might account for the greater efficacy of taxane in n-3 PUFA nutritional group. In the control nutritional group during docetaxel treatment, we noticed an increase in tumor vascularization (AUC, peak intensity and blood flow at W þ2 ) that can be attributed to vessel enlargement and/or vessel recruitment. A vessel enlargement appeared to be more relevant since a vasodilator effect of docetaxel on tumor vessels has been previously mentioned (40) . In addition, we determined that docetaxel increased Ser1177-eNOS phosphorylation in mammary tumors, as already observed by others in endothelial cells (41, 42) . The increase of eNOS phosphorylation on Ser 1177 is an important mechanism to induce eNOS activity and subsequently NO production that is known for its vasodilator properties (43, 44) . In n-3 PUFA nutritional group treated by docetaxel, neither this vessel enlargement nor the activation of eNOS phosphorylation was detected in mammary tumors, suggesting a disruption of NO signaling. Results obtained on endothelial cells were in line with the in vivo data since a lack of eNOS phosphorylation on Ser 1177 was observed in DHAsupplemented cells. NO promotes tumor angiogenesis and induces vessel hypermeability which is a cause of elevated IFP (45, 46) . Inhibition of NO synthesis in eNOS-deficient mice or in wild type treated with NO inhibitors abrogates tumor angiogenesis and vascular permeability (16, 47) . As reported by Gratton and Dimmeler using NO inhibitors, our data showed that DHA was also able to block permeability of endothelial cell monolayer and endothelial cell migration (30, 48) . The disruption of NO signaling is likely to be a key mechanism of n-3 PUFA leading to antiangiogenic effect and decrease of IFP in tumors. In addition, since tumor IFP is influenced to systemic blood pressure as reported previously (49), a potential variation of systemic blood pressure following n-3 PUFA might affect the magnitude of the IFP decrease. In this study, the cardiac frequency has been measured and no difference was found regardless of diet (data not shown). These results were consistent with a previous study where no hemodynamic cardiac alterations were observed in rats receiving anthracyclines under n-3 PUFA diet (50) .
The consequence of eNOS inhibition on decreased permeability and increased molecule extravasation highlighted a paradox already described by others (51,52). Tong et al. (39) reported that a drop in vascular permeability induces transvascular pressure gradients implied in convection. Convection is governed by pressure gradients, made up of three components: microvascular pressure, IFP and osmotic pressure. Convection with diffusion governs the movement of anticancer drugs across vessel walls. In the context of permeable vessels in tumor, osmotic pressure gradient is weak and has minimal effects on transvascular flow (39) . We propose a model to explain the effects of n-3 PUFA on transvascular convection leading to the increased extravasation of molecules ( Figure 5 ). In untreated tumors, Fig. 4 . DHA blocked the VEGF-induction of HUVEC migration, monolayer permeability and eNOS phosphorylation. (A) Permeability assays. Control and DHA-supplemented HUVEC monolayers were stimulated with VEGF (10 ng/ml; 1 h). The permeability was measured by FITC-dextran leakage through endothelial monolayer. Data are mean ± SEM from three independent experiments performed in duplicate, ÃÃÃ P , 0.001, analysis of variance followed by a Newman-Keuls test. (B) Migration assays. Control and DHA-supplemented HUVEC cells were stimulated with VEGF (10 ng/ml, 5 h). Deta-NO was used as an NO donor (10 lM). Data are mean ± SEM (at least, four independent experiments in each condition), ÃÃÃ P , 0.001, ## P , 0.01 and ### P , 0.001 compared with DHA condition, analysis of variance followed by a Newman-Keuls test. (C) eNOS phosphorylation. Control and DHA-supplemented HUVEC were stimulated with VEGF (10 ng/ml, 1 h). Cell extracts were analyzed by western blotting for Ser1177P-eNOS and pan eNOS expression. Results were quantified by densitometry and expressed by the ratio P-eNOS/pan eNOS normalized to control condition (on the right). Data are mean (P-eNOS/pan eNOS) ± SEM from five independent experiments. Ã P , 0.05, analysis of variance followed by a Newman-Keuls test.
n-3 PUFA potentiate docetaxel treatment by decreasing IFP elevated IFP (15 mmHg) could equalize or exceed the microvascular pressure and, thus, cause a null or negative net outward filtration pressure (14) . In tumors treated by docetaxel alone, eNOS activation could explain the vasodilatation and decrease in microvascular pressure as already reported (40) . The resultant filtration pressure would be neutralized since we measured that IFP was also slightly decreased (12 mmHg) under docetaxel. In these conditions, extravasation of anticancer drugs would be mostly governed by diffusion. In n-3 PU-FA nutritional group treated by docetaxel, eNOS remained inactivated, resulting in a decrease of permeability and a subsequent IFP reduction (9 mmHg). Therefore, n-3 PUFA would promote the establishment of a net outward positive pressure in the same direction as diffusion and subsequently improved anticancer drug extravasation and therapeutic effects. Inadequate drug delivery is a major cause of drug resistance and methods of enhancing chemotherapy delivery to solid tumors remain a major interest in medicine. This study reports that n-3 PUFA display antiangiogenic properties and normalize function of tumor vasculature to make it more efficient for molecule delivery. Finally, the preclinical data reported here strengthen the findings of two published Phase II trial using PUFA for patients treated for breast and lung cancer (3, 5) and reinforce the rationale for a Phase III clinical studies testing n-3 PUFA supplementation during conventional cancer treatment. Supplementary Figures 1 and 2 can be found at http://carcin. oxfordjournals.org/
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Ligue Nationale contre le Cancer; Cancéropôle Grand Ouest; Institut National de la Santé et de la Recherche Médicale; Fonds Européens de Développement Régional (FEDER); Région Centre; Ministère de l'Enseignement Supérieur et de la Recherche; the Ligue Nationale contre le Cancer (to S.V.); the Association Nationale de la Recherche Technique (convention CIFRE of S.K.); the University Hospital'Bretonneau', Tours (C.G.). In an untreated tumor, the net outward filtration pressure is known to be null or negative (left picture). Docetaxel application leads to a decrease in microvascular pressure subsequent to the vessel dilatation (due to eNOS activation and NO production) and to a slight decrease of IFP (12 mmHg, central picture). Thus, the net outward pressure remains neutral. In docetaxel-treated tumors and enriched with n-3 PUFA, eNOS activation does not occur leading to a decrease of permeability and IFP (9 mmHg) (right picture). In these conditions, n-3 PUFA promote the establishment of a net outward positive pressure in the same direction as diffusion of anticancer agents.
